NASDAQ:MNOV MediciNova - MNOV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.21 +0.01 (+0.45%) (As of 03/24/2023 02:14 PM ET) Add Compare Share Share Today's Range$2.17▼$2.2550-Day Range$1.95▼$2.5252-Week Range$1.89▼$3.18Volume4,161 shsAverage Volume27,787 shsMarket Capitalization$108.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MediciNova MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.08Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.30) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.92 out of 5 starsMedical Sector984th out of 989 stocksPharmaceutical Preparations Industry477th out of 480 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for MediciNova. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.78% of the float of MediciNova has been sold short.Short Interest Ratio / Days to CoverMediciNova has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in MediciNova has recently decreased by 0.19%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMediciNova does not currently pay a dividend.Dividend GrowthMediciNova does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNOV. Previous Next 1.7 News and Social Media Coverage News SentimentMediciNova has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MediciNova this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added MediciNova to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediciNova insiders have not sold or bought any company stock.Percentage Held by Insiders16.70% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.18% of the stock of MediciNova is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediciNova are expected to decrease in the coming year, from ($0.30) to ($0.34) per share.Price to Book Value per Share RatioMediciNova has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MediciNova (NASDAQ:MNOV) StockMediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.Read More Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address MNOV Stock News HeadlinesMarch 22, 2023 | americanbankingnews.comMediciNova (NASDAQ:MNOV) & Enlivex Therapeutics (NASDAQ:ENLV) Head-To-Head ContrastMarch 20, 2023 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Now Covered by StockNews.comMarch 24, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 9, 2023 | finance.yahoo.comMediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryFebruary 27, 2023 | finance.yahoo.comMNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled…February 20, 2023 | finance.yahoo.comMediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and TherapeuticsFebruary 8, 2023 | finance.yahoo.comMediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVIDJanuary 30, 2023 | finance.yahoo.comMediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use DisorderMarch 24, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.January 12, 2023 | finance.yahoo.comMediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed GlioblastomaJanuary 11, 2023 | finance.yahoo.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in CanadaJanuary 9, 2023 | finance.yahoo.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in BrazilJanuary 5, 2023 | finance.yahoo.comMediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)December 6, 2022 | finance.yahoo.comMediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes FederationDecember 5, 2022 | finance.yahoo.comMediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol AbuseNovember 18, 2022 | finance.yahoo.comMNOV: Well Financed to Get Through Tough Market Conditions…October 13, 2022 | finance.yahoo.comWe Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business GrowthOctober 6, 2022 | reuters.comMNOV.A - MediciNova, Inc. | Stock Price & Latest News | ReutersSeptember 29, 2022 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.comSeptember 16, 2022 | seekingalpha.comMediciNova to get US patent for MN-166 to treat brain cancer - Seeking AlphaSeptember 15, 2022 | globenewswire.comMediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference - GlobeNewswireSeptember 15, 2022 | finance.yahoo.comMediciNova to Participate in the Lytham Partners Fall 2022 Investor ConferenceSeptember 15, 2022 | globenewswire.comMediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma - GlobeNewswireSeptember 14, 2022 | nasdaq.comHealth Care Sector Update for 09/14/2022: MNOV, PNT, MRNA, XLV, IBB - NasdaqSeptember 14, 2022 | finance.yahoo.comMediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of GlioblastomaSeptember 14, 2022 | seekingalpha.comMediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disordersSeptember 14, 2022 | finance.yahoo.comMediciNova Poised To Receive Canadian Patents For Cholesterol CandidatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address MNOV Company Calendar Last Earnings10/26/2020Today3/24/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNOV CUSIPN/A CIK1226616 Webmedicinova.com Phone(858) 373-1500Fax858-404-0048Employees11Year Founded2000Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,060,000.00 Net MarginsN/A Pretax Margin-2,628,577.25% Return on Equity-18.73% Return on Assets-17.69% Debt Debt-to-Equity RatioN/A Current Ratio18.51 Quick Ratio18.51 Sales & Book Value Annual Sales$4.04 million Price / Sales26.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book1.53Miscellaneous Outstanding Shares49,050,000Free Float40,855,000Market Cap$107.42 million OptionableOptionable Beta0.98 Social Links Key ExecutivesYuichi IwakiPresident, Chief Executive Officer & DirectorJason KrugerChief Financial OfficerKazuko MatsudaDirector & Chief Medical OfficerGeoffrey G. O'BrienVice President & Executive OfficerDavid H. CreanChief Business OfficerKey CompetitorsLifecore BiomedicalNASDAQ:LFCREyenoviaNASDAQ:EYENLongboard PharmaceuticalsNASDAQ:LBPHEton PharmaceuticalsNASDAQ:ETONXBiotechNASDAQ:XBITView All CompetitorsInsiders & InstitutionsJane Street Group LLCBought 267,824 shares on 2/15/2023Ownership: 0.546%Millennium Management LLCSold 101,330 shares on 2/15/2023Ownership: 0.513%Virtu Financial LLCBought 25,674 shares on 2/15/2023Ownership: 0.052%Morgan StanleyBought 10,852 shares on 2/15/2023Ownership: 0.046%Squarepoint Ops LLCBought 18,744 shares on 2/15/2023Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions MNOV Stock - Frequently Asked Questions Should I buy or sell MediciNova stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNOV shares. View MNOV analyst ratings or view top-rated stocks. How have MNOV shares performed in 2023? MediciNova's stock was trading at $2.05 at the beginning of 2023. Since then, MNOV shares have increased by 6.8% and is now trading at $2.19. View the best growth stocks for 2023 here. When is MediciNova's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our MNOV earnings forecast. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) announced its earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY). What is MediciNova's stock symbol? MediciNova trades on the NASDAQ under the ticker symbol "MNOV." Who are MediciNova's major shareholders? MediciNova's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.89%), Jane Street Group LLC (0.55%), Millennium Management LLC (0.51%), JPMorgan Chase & Co. (0.51%), HRT Financial LP (0.37%) and Bank of America Corp DE (0.36%). View institutional ownership trends. How do I buy shares of MediciNova? Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MediciNova's stock price today? One share of MNOV stock can currently be purchased for approximately $2.19. How much money does MediciNova make? MediciNova (NASDAQ:MNOV) has a market capitalization of $107.42 million and generates $4.04 million in revenue each year. How can I contact MediciNova? MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048. This page (NASDAQ:MNOV) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.